Tissue-Specific Human Extracellular Matrix Scaffolds Promote Pancreatic Tumour Progression and Chemotherapy Resistance
Walid Al-Akkad,
Pilar Acedo,
Maria-Giovanna Vilia,
Luca Frenguelli,
Alexander Ney,
Irene Rodriguez-Hernandez,
Peter L. Labib,
Domenico Tamburrino,
Gabriele Spoletini,
Andrew R. Hall,
Simone Canestrari,
Anna Osnato,
Jose Garcia-Bernardo,
Leinal Sejour,
Vessela Vassileva,
Ioannis S. Vlachos,
Giuseppe Fusai,
Tu Vinh Luong,
Steven R. Whittaker,
Stephen P. Pereira,
Ludovic Vallier,
Massimo Pinzani,
Krista Rombouts,
Giuseppe Mazza
Affiliations
Walid Al-Akkad
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Pilar Acedo
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Maria-Giovanna Vilia
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Luca Frenguelli
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Alexander Ney
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Irene Rodriguez-Hernandez
Engitix Therapeutics, The Westworks, 195 Wood Lane, Shepherd’s Bush, London W12 7FQ, UK
Peter L. Labib
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Domenico Tamburrino
Division of Surgery, Royal Free London NHS Foundation Trust, University College London, London NW3 2QG, UK
Gabriele Spoletini
Division of Surgery, Royal Free London NHS Foundation Trust, University College London, London NW3 2QG, UK
Andrew R. Hall
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Simone Canestrari
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Anna Osnato
Wellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory, University of Cambridge, Cambridge CB2 0AW, UK
Jose Garcia-Bernardo
Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1RQ, UK
Leinal Sejour
Cancer Research Institute, HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
Vessela Vassileva
Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK
Ioannis S. Vlachos
Cancer Research Institute, HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
Giuseppe Fusai
Division of Surgery, Royal Free London NHS Foundation Trust, University College London, London NW3 2QG, UK
Tu Vinh Luong
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Steven R. Whittaker
Engitix Therapeutics, The Westworks, 195 Wood Lane, Shepherd’s Bush, London W12 7FQ, UK
Stephen P. Pereira
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Ludovic Vallier
Wellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory, University of Cambridge, Cambridge CB2 0AW, UK
Massimo Pinzani
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Krista Rombouts
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Giuseppe Mazza
UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK
Over 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed at a late stage and are locally advanced or with concurrent metastases. The aggressive phenotype and relative chemo- and radiotherapeutic resistance of PDAC is thought to be mediated largely by its prominent stroma, which is supported by an extracellular matrix (ECM). Therefore, we investigated the impact of tissue-matched human ECM in driving PDAC and the role of the ECM in promoting chemotherapy resistance. Decellularized human pancreata and livers were recellularized with PANC-1 and MIA PaCa-2 (PDAC cell lines), as well as PK-1 cells (liver-derived metastatic PDAC cell line). PANC-1 cells migrated into the pancreatic scaffolds, MIA PaCa-2 cells were able to migrate into both scaffolds, whereas PK-1 cells were able to migrate into the liver scaffolds only. These differences were supported by significant deregulations in gene and protein expression between the pancreas scaffolds, liver scaffolds, and 2D culture. Moreover, these cell lines were significantly more resistant to gemcitabine and doxorubicin chemotherapy treatments in the 3D models compared to 2D cultures, even after confirmed uptake by confocal microscopy. These results suggest that tissue-specific ECM provides the preserved native cues for primary and metastatic PDAC cells necessary for a more reliable in vitro cell culture.